Published in Hepatitis Weekly, August 1st, 2005
The company also announced the presentation at the World Allergy Congress in Munich, Germany of positive interim results from the first 120 attacks of hereditary angioedema (HAE) treated with intravenously administered DX-88 in its open-label, repeat-dosing, phase II trial referred to as EDEMA2. DX-88 is being developed in a joint venture with Genzyme Corp. for the treatment of HAE, a debilitating and life-threatening inflammatory condition characterized by unpredictable attacks of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.